VISCERAL ADIPOSITY AS A GLOBAL FACTOR OF CARDIOVASCULAR RISK
https://doi.org/10.15829/1560-4071-2018-5-7-14
Abstract
Obesity becomes one of the main risk factors of development and progression of cardiovascular diseases. Association of the high values of body mass index with overall and cardiovascular mortality is confirmed by the results of meta-analyses of multiple prospective studies. On the other hand, the two most global problems of this relationship — “obesity paradox” and heterogeneity of obesity phenotypes by cardiometabolic risk, released multiple discussions on the issues of predictive value of body overweight and obesity, and worth of correction in patients under the secondary prevention framework. Nowadays, the fact became obvious that maximum role in the risk raise plays a specific type of adipous tissue, and morphological changes in visceral adipous tissue within the processess of remodeling and inflammation, with further dysfunction. In the article, an assessment provided of the ethiopathogenetic role of visceral adipous tissue in cardiovascular continuum; a review provided of the verification approaches to visceral obesity, and a strategy proposed for cardiovascular risk stratification in association with obesity, in a broad clinical framework.
About the Authors
G. A. Chumakova
Altai State Medical University of the Ministry of Health
Russian Federation
Competing Interests: Barnaul
Russian Federation
Competing Interests: Barnaul
T. Yu. Kuznetsova
Petrozavodsk State University
Petrozavodsk
Petrozavodsk
M. A. Druzhilov
Medical-sanitary Institution of the FSS in Karelia Republic
Petrozavodsk
Petrozavodsk
N. G. Veselovskaya
Altai State Medical University of the Ministry of Health;
Altaiskiy Kray Cardiological Dispensary
Barnaul
Barnaul
References
1. Lim S, Vos T, Flaxman A, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2224-60. DOI: 10.1016/S0140-6736(12)61766-8.
2. Marie N, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766-81. DOI: 101016/S0140-6736(14)60460-8.
3. The GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med 2017; 377: 13-27. DOI: 101056/NEJMoa1614362.
4. Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012-2013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention 2014; 13 (6): 4-11. (In Russ.)
5. Oganov RG, Maslennikova GYa. Demographic trends in the Russian Federation: the impact of cardiovascular disease. Cardiovascular Therapy and Prevention 2012; 11 (1): 5-10. (In Russ.)
6. Piepoli М, Hoes А, Agewall S, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2016). European Heart Journal 2016; 37 (29): 231581. DOI: 10.1016/j.atherosclerosis.2016.05.037.
7. The Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: individual participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016; 388: 776-86. DOI: 10.1016/S0140-6736(16)30175-1.
8. Aune D, Sen A, Prasad M, et al. BMI and all-cause mortality: systematic review and nonlinear dose-response metaanalysis of 230 cohort studies with 3,74 million deaths among 30,3 million participants. BMJ 2016; 353: i2156. DOI: 101136/bmj.i2156.
9. Antonopoulos A, Tousoulis D. The molecular mechanisms of obesity paradox. Cardiovascular Research 2017; 113: 1074-86. DOI: 101093/cvr/cvx106.
10. Samocha-Bonet D, Dixit V, Kahn C, et al. Metabolically healthy and unhealthy obese: the 2013 Stock Conference report. Obes Rev 2014; 15: 697-708. DOI: 10.1111/obr.12199.
11. Ortega F, Lavie C, Blair S. Obesity and Cardiovascular Disease. Circ Res 2016; 118: 175270. DOI: 10.1161/CIRCRESAHA.115.306883.
12. Nuttall F. Body mass index: obesity, BMI, and health: a critical review. Nutr Today 2015; 50: 117-28. DOI: 10.1097/NT.0000000000000092.
13. Druzhilov MA, Druzhilova OYu, Kuznetsova TYu, et al. Obesity as cardiovascular risk factor: accent on quality and functional activity of adipose tissue. Russ J Cardiol 2015; 4: 111-7. (In Russ.)
14. Sun K, Kusminski C, Scherer P. Adipose tissue remodeling and obesity. J Clin Invest 2011; 121 (6): 2094-101. DOI: 10.1172/JCI45887.
15. Romantsova TI, Ostrovskaya EV. Metabolically healthy obesity: definitions, protective factors, clinical relevance. Almanac of Clinical Medicine 2015; 1 (1): 75-86. (In Russ.)
16. Nakamura K, Fuster J, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol 2014; 63 (4): 250-9. DOI: 101016/j.jjcc.201311.006.
17. Titov VN, Dmitriev VA. Obesity is a pathology of adipocytes: cell number, arterial bed volume, local circulation pools in vivo, natriuretic peptides and arterial hypertension. Translational Medicine 2015; 1: 26-38. (In Russ.)
18. Tchernof А, Despres J. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013; 93: 359-404. DOI: 101152/physrev.00033.2011.
19. Ott AV, Chumakova GA, Veselovskaya NG. A resistance to leptin in development of different obesity phenotypes. Russ J Cardiol 2016; (4): 14-8. (In Russ)
20. Wang Y, Ma X, Lau W. Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin Receptor Modification. Trends in Endocrinology & Metabolism 2017; 28 (7): 519-30. DOI: 10.1016/j.tem.2017.03.004.
21. Sun K, Kusminski C, Scherer P. Adipose tissue remodeling and obesity. J Clin Invest 2011; 121 (6): 2094-101. DOI: 10.1172/JCI45887.
22. Vecchie A, Dallegri F, Carbone F, et al. Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur J Intern Med 2018; 48: 6-17. DOI: 101016/j. ejim.2017.10.020.
23. Molica F, Morel S, Kwak B, et al. Adipokines at the crossroad between obesity and cardiovascular disease. Thromb Haemost 2015; 113 (3): 553-66. DOI: 10.1160/TH14-060513.
24. Badimon L, Bugiardini R, Cenko E, et al. Position paper of the European Society of Cardiology-working group of coronary pathophysiology and microcirculation: obesity and heart disease. Eur Heart J 2017; 38: 1951-8. DOI: 10.1093/eurheartj/ehx181.
25. Liu J, Fox C, Hickson D, et al. Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study. Arterioscler Thromb Vasc Biol 2011; 31 (11): 2715-22. DOI: 10.1161/ATVBAHA.111.234062.
26. Lee J, Pedley A, Hoffmann U, et al. Association of Changes in Abdominal Fat Quantity and Quality with Incident Cardiovascular Disease Risk Factors. J Am Coll Cardiol 2016; 68 (14): 1509-21. DOI: 10.1016/j.jacc.2016.06.067.
27. Britton K, Massaro J, Murabito J, et al. Body Fat Distribution, Incident Cardiovascular Disease, Cancer, and All-Cause Mortality. J Am Coll Cardiol 2013; 62 (10): 921-5. DOI: 10.1016/j.jacc.2013.06.027.
28. Koster A, Murphy R, Eiriksdottir G, et al. Fat distribution and mortality: the AGES-Reykjavik study. Obesity (Silver Spring) 2015; 23 (4): 893-7. DOI: 10.1002/oby.21028.
29. Matsuzawa Y, Funahashi T, Nakamura T. The Concept of Metabolic Syndrome: Contribution of Visceral Fat Accumulation and Its Molecular Mechanism. J Atheroscler Thromb 2011; 18 (8): 629-39. DOI: 10.5551/jat.7922.
30. Chumakova GA, Veselovskaya NG, Gritsenko OV, et al. Metabolic syndrome: challenging and unresolved issues. Russ J Cardiol 2014; 3: 63-71. (In Russ.)
31. Gonzalez N, Moreno-Villegas Z, Gonzalez-Bris A, et al. Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes. Cardiovasc Diabetol 2017; 16 (1): 44. DOI: 10.1186/s12933-017-0528-4.
32. Chumakova GA, Veselovskaya NG. Methods of visceral obesity assessment in clinical practice. Russ J Cardiol 2016; 4: 89-96. (In Russ.)
33. Morelli M, Gaggini M, Daniele G, et al. Ectopic fat: the true culprit linking obesity and cardiovascular disease? Thromb Haemost 2013; 110 (4): 651-60. DOI: 101160/TH13-040285.
34. Iacobellis G, Bianco А. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab 2011; 22 (11): 450-7. DOI: 10.1016/j.tem.2011.07.003.
35. Salazar J, Luzardo E, Mejias J, et al. Epicardial Fat: Physiological, Pathological, and Therapeutic Implications. Cardiol Res Pract 2016; 2016: 1291537. DOI: 10.1155/2016/1291537.
36. Chumakova GA, Veselovskaya NG. Clinical significance of visceral obesity. Moscow: GEOTAR-Media, 2016. p. 200. (In Russ.)
37. Druzhilov MA, Beteleva YE, Druzhilova OY, et al. The role of epicardial obesity in the development of structural and functional remodeling of the heart. Russ J Cardiol 2017; 4: 35-9. (In Russ.)
38. Druzhilov MA, Kuznetsova TY. Obesity associated atrial fibrillation: epicardial fat tissue in etiopathogenesis. Russ J Cardiol 2017; 7: 178-84. (In Russ.)
39. Druzhilov MA, Kuznetsova TY. Visceral obesity as risk factor of early vascular aging. Cardiologiia 2016; 2 (56): 52-6. (In Russ.)
40. Mahabadi A, Berg M, Lehmann N, et al. Association of Epicardial Fat With Cardiovascular Risk Factors and Incident Myocardial Infarction in the General Population. The Heinz Nixdorf Recall Study. J Am Coll Cardiol 2013; 61 (13): 1388-95. DOI: 101016/j. jacc.2012.11.062.
41. Veselovskaya NG, Chumakova GA, Elykomov VA, et al. Restenosis risk factors after coronary artery stenting in obese patients. Cardiovascular Therapy and Prevention 2013; 12 (3): 4-9. (In Russ.)
42. Coutinho T, Goel K, Correa de Sa D, et al. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of “normal weight central obesity”. J Am Coll Cardiol 2013; 61 (5): 553-60. DOI: 101016/j. jacc.2012.10.035.
43. Amato M. Cut-off points of the visceral adiposity index identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis 2011; 10 (183): 1-8. DOI: 10.1186/1476-511X-10-183.
44. Mauad F, Chagas-Neto F, Benedeti A, et al. Reproducibility of abdominal fat assessment by ultrasound and computed tomography. Radiol Bras 2017; 50 (3): 141-7. DOI: 101590/0100-3984.2016.0023.
45. Kuznetsova TY, Chumakova GA, Druzhilov MA, et al. Clinical application of quantitative echocardiographic assessment of epicardial fat tissue in obesity. Russ J Cardiol 2017; 4: 81-7. (In Russ.)
46. Guo F, Garvey W. Development of a Weighted Cardiometabolic Disease Staging (CMDS) System for the Prediction of Future Diabetes. J Clin Endocrinol Metab 2015; 100 (10): 3871-7. DOI: 10.1210/jc.2015-2691.
47. Garvey W, Garber A, Mechanick J, et al. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract 2014; 20 (9): 977-89. DOI: 10.4158/EP14280.PS.
48. Shlyakhto EV, Nedogoda SV, Konradi АО, et al. The concept of novel national clinical guidelines on obesity. Russ J Cardiol 2016; 4: 7-13. (In Russ.)
49. Samorodskaya IV, Bolotova EV, Boytsov SA. Current issues of obesity classification. Cardiovascular Therapy and Prevention 2015; 14 (4): 103-10. (In Russ.)
Review
For citations:
Chumakova G.A., Kuznetsova T.Yu., Druzhilov M.A., Veselovskaya N.G. VISCERAL ADIPOSITY AS A GLOBAL FACTOR OF CARDIOVASCULAR RISK. Russian Journal of Cardiology. 2018;(5):7-14. (In Russ.) https://doi.org/10.15829/1560-4071-2018-5-7-14
Views:
5217
Email this article 